At its November meeting, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended seven drugs for approval, as well as two line extensions. The committee also started the re-examination of a previous negative opinion on one medicine, while three companies withdrew marketing applications. All of the decisions can be found detailed below.
Positive recommendations on new medicines:
Positive recommendations on extensions of therapeutic indications:
Start of re-examination of recommendation for new medicine:
Withdrawal of marketing authorisation applications:
To read more Top Story articles, click here.